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Background
Many infections are associated with antiphospholipid antibodies (aPLs). The purpose of 
this study was to investigate the prevalence, persistence, clinical significance, and charac-
teristics of aPLs in hepatitis B virus (HBV)-infected patients.
Methods
This study included 143 patients with HBV infection and 32 healthy individuals as 
controls. The presence of anticardiolipin antibodies (aCL Ab), anti-β2-glycoprotein I anti-
bodies (β2GPI Ab), and lupus anticoagulant (LA) was assessed.
Results
The total prevalence of aPLs in HBV-infected patients was 12.6% (18 of 143). Of these 
18 patients, 15 had low to medium titers of aCL Ab (10 with IgM, 4 with IgG, and 1 with 
both isotypes). β2GPI Ab and LA were detected in 3 (2.1%) and 2 (1.4%) patients with 
HBV infection, respectively. In follow-up specimens from 14 patients with elevated levels 
of aCL Ab or β2GPI Ab, 10 (71.4%) showed the persistent presence of aPLs. No clinical 
manifestations related to aPLs were identified.
Conclusion
In HBV-infected patients, the most frequently detected antiphospholipid antibodies were 
IgM aCL Ab, which have a weak association with the clinical manifestations of APS. Unlike 
the transient presence reported for other infection-associated aPLs, most aPLs were per-
sistently detected over a 12-week period in patients with HBV infection.
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INTRODUCTION
  Antiphospholipid antibodies (aPLs) are a heterogeneous 
group of autoantibodies or alloantibodies with an affinity 
for anionic phospholipids [1]. aPLs occur in patients with 
antiphospholipid syndrome (APS), systemic lupus eryth-
ematosus (SLE), and various other rheumatic diseases. Fur-
thermore, an elevated level of aPLs is recognized as a risk 
factor for thrombosis [2]. Several studies have suggested that 
the pathogenic mechanisms of aPLs are related to platelet 
activation, endothelial cell activation, and activation of the 
complement cascade [3, 4]; however, their pathogenic func-
tions in patients with autoimmune diseases like SLE and 
primary APS are not fully understood. 
  aPLs have also been detected in numerous infectious dis-
eases, including those caused by parvovirus B19, cytomegalo-
virus, varicella-zoster virus, human immunodeficiency virus 
(HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), 
Helicobacter pylori, streptococci, and staphylococci [5-7]. 
The reported prevalence of aPLs in infected patients varies 
across studies [5, 8]. The variation in prevalence between 
studies may be partly due to differences in infection types, 
antibody types, and aPL measurement methods. For example, 
in HIV patients, a high prevalence of anticardiolipin anti-
bodies (aCL Ab) (46.5%) [8] and lupus anticoagulant (LA) 
(43%) [9] was reported. In contrast, anti-β2-glycoprotein 
I antibodies (β2GPI Ab) were rarely detected in HIV patients 
[5].
  The clinical significance of aPLs associated with various 
infections is controversial. In many studies, the presence 
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Table 1. Prevalence of antiphospholipid antibodies (aCL Ab, β2GPI Ab, and lupus anticoagulant) in HBV-infected patients.
aCL Ab β2GPI Ab  Lupus 
anticoagulant
Total (%)
IgM type IgG type IgM & IgG IgM type IgG type
HBV-infected patients (N=143) 10 4 1 1 2 2 18 (12.6%)
Normal controls (N=32)   1 0 0 0 0 0 1 (3.1%)
Abbreviations: HBV, hepatitis B virus; aCL Ab, anticardiolipin antibodies; β2GPI Ab, anti-β2-glycoprotein I antibodies.
non-pathogenic [5, 8]; however, in patients with various 
infections, thrombotic manifestations such as portal vein 
thrombosis and pulmonary embolism have been reported 
[10-13].
Recently, several studies showed a higher prevalence of 
aCL Ab in chronic viral hepatitis patients than in control 
individuals [14-17]. In the present study, we investigated 
the prevalence, persistence, clinical significance, and charac-
teristics of aPLs in HBV-infected patients.
MATERIALS AND METHODS
1. Patient selection
　The prevalence of aPLs was prospectively determined in 
HBV-infected patients and healthy controls who visited the 
Gastroenterology Department of the Bundang CHA hospital 
between 2008 and 2009. This study included 143 HBV-in-
fected patients, irrespective of their treatment (59 women 
and 84 men; age range, 16-71 years; mean, 42.7 years), and 
32 healthy individuals as controls (13 women and 19 men; 
age range, 27-65 years; mean, 40 years). All patients with 
HBV infection tested positive for HBV surface antigen 
(HBsAg) or HBV DNA and negative for anti-HCV antibody. 
Informed consent was obtained from all patients. The patients 
were divided into 2 groups on the basis of the hepatitis 
B e antigen and antibody (HBeAg, HBeAb) status and serum 
HBV DNA level: chronic hepatitis B patients (N=97) and 
patients with inactive HBsAg carrier state (N=46) [18]. 
Patients with positive HBeAg or high levels of HBV DNA 
(≥10
4 copies/mL) were considered chronic hepatitis B pa-
tients, and patients with negative HBeAg and low HBV DNA 
level (＜10
4 copies/mL) were considered inactive HBsAg 
carriers. All normal controls were negative for HBsAg, anti- 
HCV antibody, anti-HIV antibody, and antinuclear antibody. 
Alanine aminotransferase (ALT) levels were normal (5-40 
IU/L) in all healthy controls. Thromboembolic complications 
associated with aPLs were identified through medical record 
review. The local ethics committee of CHA Bundang Medical 
Center approved this study. 
2. aCL Ab
  aCL Ab (IgG and IgM isotype) were measured using a 
commercial enzyme-linked immunosorbent assay (ELISA) 
(Zeus Scientific Inc., Raritan, NJ). According to the manu-
facturer’s instructions, the cut-off values for positivity were 
20 GPL or MPL (IgG or IgM phospholipid units). Specimens 
with less than 20 GPL or MPL in the initial ELISA were 
considered negative. Specimens with greater than 20 GPL 
or MPL in the initial ELISA were retested in duplicate. 
The specimens were considered positive, when the value 
was repeatedly greater than 20 GPL or MPL. 
3. β2GPI Ab
  β2GPI Ab (IgG and IgM isotype) were measured using 
a commercial ELISA (INOVA Diagnostics, Inc., San Diego, 
CA, USA). According to the manufacturer’s instructions, the 
cut-off values for positivity are 20 SGU or SMU (standard 
IgG or standard IgM units). Specimens with less than 20 
SGU or SMU in the initial ELISA were considered negative. 
Specimens with greater than 20 SGU or SMU in the initial 
ELISA result were retested in duplicate. The specimens were 
considered positive when the value was repeatedly greater 
than 20 SGU or SMU. 
4. LA
　All plasma samples from patients and normal individuals 
were evaluated for the presence of LA according to the 
criteria defined by the Subcommittee on LA/antiphospho-
lipid antibody of the International Society of Thrombosis 
and Haemostasis [19]. LA was measured by performing the 
dilute Russell’s viper venom test using the HemosIL Kit 
(Instrumentation Laboratory, Milano, Italy).
5. Statistical analysis
　Statistical analyses were performed using SAS Statistical 
Analysis Software Version 9.1 (SAS Institute Inc., Cary, NC, 
USA). A chi-square test was used to determine the difference 
in the presence of aPLs between the chronic viral hepatitis 
patient group and the control group. 
RESULTS
  The total prevalence of aPLs (aCL Ab, β2GPI Ab, or LA) 
in HBV-infected patients was 12.6% (18 of 143) (Table 1). 
Among these 18 patients, aPLs were detected in 15 of 97 
chronic hepatitis B patients and 3 of 46 inactive HBsAg 
carrier patients. No clinical manifestations related to aPLs 
were identified. Among the 143 HBV-infected patients, 15 
patients (10.5%) had a low to moderate level of aCL Ab 
(10 with IgM, 4 with IgG, and 1 with both isotypes) compared Korean J Hematol 2011;46:36-40.
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Table 2. Characteristics of HBV-infected patients with antiphospholipid antibodies and the types of antiphospholipid antibodies.
Patient ID Gender Age Status of HBV infection
a) Type of antiphospholipid antibodies
021
058
062
082
098
099
104
112
114
122
130
134
137
140
144
149
150
153
M
F
M
F
F
M
F
F
F
F
F
F
M
M
M
F
M
F
43
39
34
61
42
34
46
26
39
40
37
70
52
45
47
64
47
28
Inactive HBsAg carrier
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Inactive HBsAg carrier
Chronic hepatitis B
Chronic hepatitis B
Chronic hepatitis B
Inactive HBsAg carrier
Chronic hepatitis B
Chronic hepatitis B
IgG and IgM aCL
IgM β2GPI and LA
IgG β2GPI
IgM aCL
IgG aCL
IgM aCL
IgM aCL
IgG aCL
IgG aCL
IgM aCL
IgM aCL and IgG β2GPI 
IgM aCL
LA
IgG aCL
IgM aCL
IgM aCL
IgM aCL
IgM aCL
a)Patients were divided into 2 groups on the basis of the hepatitis B e antigen and antibody status and the HBV DNA level: chronic hepatitis
B patients and patients with inactive HBsAg carrier state.
Abbreviations: HBV, hepatitis B virus; M, male; F, female; aCL, anticardiolipin antibodies; β2GPI, anti-β2-glycoprotein I antibodies; LA, lupus
anticoagulant.
Fig. 1. Distribution of anticardiolipin antibody titers in hepatitis B virus (HBV)-infected patients and normal controls, IgM isotype (A) and IgG isotype
(B).
to only 1 of the 32 control subjects (3.1%). The difference 
between the groups was not significant (P=0.19). The median 
values for aCL Ab IgM and IgG isotypes were 28.1 MPL 
(range, 23.4-42.2) and 32.9 GPL (range, 20.5-47.2), respec-
tively (Table 2 and Fig. 1). 
　The prevalence of β2GPI Ab and the LA activity in the 
HBV-infected patient group was 2.1% (3 of 143) and 1.4% 
(2 of 143), respectively. In contrast, none of the healthy 
controls had elevated levels of β2GPI Ab or LA; however, 
the difference between the groups was not significant (P= 
0.40). The isotype distribution for β2GPI Ab in HBV-infected 
patients was 1 with IgM and 2 with IgG. Two HBV-infected 
patients simultaneously had 2 types of aPLs; 1 patient had 
IgM aCL Ab with cofactor dependency (β2GPI Ab, IgG type), 
and the other had β2GPI Ab (IgM type) and LA. 
　Follow-up specimens were obtained from 14 of the 17 
patients with elevated levels of aCL Ab or β2GPI Ab (11 
with aCL Ab, 2 with anti-β2GPI Ab, and 1 with both aCL 
Ab and β2GPI Ab). The median follow-up duration was 30 
weeks (range, 9-100 weeks). The aPLs persisted in 10 of 
the 14 patients (71.4%), and β2GPI Ab persisted in all 3 
patients with β2GPI Ab (Table 3).
DISCUSSION
  aPLs have been found not only in patients with auto-
immune diseases like SLE, but also in patients with various Korean J Hematol 2011;46:36-40.
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Table 3. Follow-up duration and results of aCL Ab and β2GPI Ab testing in antiphospholipid antibody-positive HBV-infected patients.
Patient
ID
Initial results Follow-up results Follow-up duration
(weeks) IgM type IgG type IgM type IgG type
aCL Ab
(MPL or GPL)
021
082
098
099
104
112
114
122
130
144
149
150
134
a)
140
a)
153
a)
26.6
27.5
−
42.2
36.3
−
−
23.4
28.7
28.1
40.4
26.9
39.8
−
25.8
47.2
−
32.9
−
−
20.5
34.7
−
−
−
−
−
−
31.5
−
−
−
−
54.2
−
−
−
27.5
46.3
−
38.2
27.8
NT
NT
NT
66.0
−
24.6
−
−
39.4
39.9
−
−
−
−
−
NT
NT
NT
100
32
9
40
71
63
36
25
28
10
25
21
β2GPI Ab
(SMU or SGU)
 
058
062
130
50.1
−
−
−
32.3
38.8
30.0
−
−
−
29.7
24.6
63
9
28
a)Follow-up specimens of 3 patients (134, 140, and 153) could not be obtained. 
Abbreviations: HBV, hepatitis B virus; aCL Ab, anticardiolipin antibodies; β2GPI Ab, anti-2-glycoprotein I antibodies; MPL, IgM phospholipid
unit; GPL, IgG phospholipid unit; SMU, standard IgM unit; SGU, standard IgG unit; -, negative; NT, not tested.
infections [5, 8]. Molecular mimicry is the proposed mecha-
nism for the development of aPLs in infections. Previous 
reports showed that antigenic determinants shared between 
the antigens of infectious agents and host tissue might trigger 
the immune response [20, 21]. However, the mechanisms 
that lead to the development of aPLs and their possible 
pathophysiological implications in patients with infections 
have not been well established. 
　The reported prevalence of aPLs in infectious patients 
is variable, in part because of a methodological problem. 
Currently, the ideal approach for standardized measurement 
for aCL Ab is under debate [22]. A discrepancy is observed 
among the different assay kits and methods, particularly 
in the lower range of antibody levels. Furthermore, one 
of the critical problems in the standardization process is 
the absence of a defined cut-off value for positivity. In pre-
vious reports, the prevalence of aCL Ab in patients with 
HBV infection was between 14% and 42% [14, 17, 23], and 
that of β2GPI Ab was 2% [17] and 7.5% [14]. In the present 
study, the prevalence of aCL Ab and β2GPI Ab was 10.5% 
and 2.1%, respectively, which was lower than that in pre-
vious reports. The lower prevalence of aCL Ab in the present 
study may be partly because of a higher cut-off value for 
positivity than that of previous reports. We used 20 GPL 
or MPL as the cut-off values, whereas 10 GPL or MPL were 
used as the cut-off values in the other reports [14, 23]. The 
prevalence of β2GPI Ab in the present study was similar 
to those in previous reports. 
　In most cases, infection-associated aPLs appear tempora-
rily and disappear within 2 or 3 months [24, 25], and except 
in rare cases, they are unrelated to thrombotic complications. 
Contrary to previous reports, in the present study, most 
aCL Ab and β2GPI Ab showed persistence and were present 
over a 12-week period. We speculated that continuous anti-
genic stimulation might be associated with persistent aPL 
production, because in the present study, the prevalence 
of aCL Ab in chronic hepatitis B patients was higher than 
that in inactive HBsAg carrier patients (15% vs. 6.5%). 
Furthermore, it was shown that in a patient with HCV in-
fection and aPLs, elimination of the virus was accompanied 
by the disappearance of aPLs, and when HCV infection re-
lapsed, aPLs also reappeared [26]. Therefore, aPLs associated 
with other chronic infections caused by HIV or HCV may 
also show persistent positivity. 
　According to a previous report [27], IgM aPLs are asso-
ciated with the clinical manifestations of APS less often 
than the IgG isotype is, and the diagnostic criteria for APS 
include only a medium or high titer of aCL Ab (＞40 GPL 
or MPL) [28]. In the present study, IgM aCL Ab were found 
more frequently (11 of 15) than the IgG isotype (5 of 15), 
and the titers of aCL Ab were mostly low. These findings 
support that infection-associated aPLs rarely manifest with 
the clinical features of APS. Because the rates of aCL Ab 
according to isotype were not provided in previous reports 
of aPLs in patients with HBV infection, comparison with 
our results was not possible. 
　In conclusion, the most frequently detected aPLs in 
HBV-infected patients were IgM aCL Ab, which has a weak 
association with the clinical manifestations of APS. Unlike 
the transient presence of other infection-associated aPLs, 
most aPLs were persistently detected over a 12-week period 
in patients with HBV infection.Korean J Hematol 2011;46:36-40.
40 Ji Young Huh, et al. 
REFERENCES
1. Levine JS, Branch DW, Rauch J. The antiphospholipid synd-
rome. N Engl J Med 2002;346:752-63. 
2. Tarr T, Lakos G, Bhattoa HP, et al. Clinical thrombotic manifes-
tations in SLE patients with and without antiphospholipid anti-
bodies: a 5-year follow-up. Clin Rev Allergy Immunol 2007; 
32:131-7. 
3. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current con-
cepts on the pathogenesis of the antiphospholipid syndrome. 
Blood 2007;109:422-30. 
4. Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated 
thrombosis: effects of aPL on endothelium and platelets. Curr 
Rheumatol Rep 2007;9:190-7. 
5. Cervera R, Asherson RA. Antiphospholipid syndrome asso-
ciated with infections: clinical and microbiological characte-
ristics. Immunobiology 2005;210:735-41. 
6. Avcin T, Toplak N. Antiphospholipid antibodies in response to 
infection. Curr Rheumatol Rep 2007;9:212-8. 
7. Sorice M, Pittoni V, Griggi T, et al. Specificity of anti-phospholi-
pid antibodies in infectious mononucleosis: a role for anti-co-
factor protein antibodies. Clin Exp Immunol 2000;120:301-6. 
8. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, anti-
phospholipid syndrome and infections. Autoimmun Rev 
2008;7:272-7. 
9. Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the ac-
quired immunodeficiency syndrome. JAMA 1986;256:491-3. 
10. Blank M, Shoenfeld Y. Beta-2-glycoprotein-I, infections, anti-
phospholipid syndrome and therapeutic considerations. Clin 
Immunol 2004;112:190-9. 
11. Gómez RM, García ES, Lacomba DL, Marchante I, Grande L, 
Fernandez MC. Antiphospholipid antibodies are related to por-
tal vein thrombosis in patients with liver cirrhosis. J Clin 
Gastroenterol 2000;31:237-40.
12. Kida Y, Maeshima E, Yamada Y. Portal vein thrombosis in a pa-
tient with hepatitis C virus-related cirrhosis complicated with 
antiphospholipid syndrome. Rheumatol Int 2009;29:1495-8.
13. Ramos-Casals M, Cervera R, Lagrutta M, et al. Clinical features 
related to antiphospholipid syndrome in patients with chronic 
viral infections (hepatitis C virus/HIV infection): description of 
82 cases. Clin Infect Dis 2004;38:1009-16. 
14. Guglielmone H, Vitozzi S, Elbarcha O, Fernandez E. Cofactor de-
pendence and isotype distribution of anticardiolipin antibodies 
in viral infections. Ann Rheum Dis 2001;60:500-4. 
15. Ordi-Ros J, Villarreal J, Monegal F, Sauleda S, Esteban I, Vilardell 
M. Anticardiolipin antibodies in patients with chronic hepatitis 
C virus infection: characterization in relation to antipho-
spholipid syndrome. Clin Diagn Lab Immunol 2000;7:241-4. 
16. Harada M, Fujisawa Y, Sakisaka S, et al. High prevalence of anti-
cardiolipin antibodies in hepatitis C virus infection: lack of ef-
fects on thrombocytopenia and thrombotic complications. J 
Gastroenterol 2000;35:272-7. 
17. Zachou K, Liaskos C, Christodoulou DK, et al. Anti-cardiolipin 
antibodies in patients with chronic viral hepatitis are in-
dependent of beta2-glycoprotein I cofactor or features of anti-
phospholipid syndrome. Eur J Clin Invest 2003;33:161-8. 
18. Lee KS, Kim DJ. Management of Chronic Hepatitis B. Korean J 
Hepatol 2007;13:447-88.
19. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diag-
nosis of lupus anticoagulants: an update. On behalf of the 
Subcommittee on Lupus Anticoagulant/Antiphospholipid Anti-
body of the Scientific and Standardisation Committee of the 
ISTH. Thromb Haemost 1995;74:1185-90. 
20. Harel M, Aron-Maor A, Sherer Y, Blank M, Shoenfeld Y. The in-
fectious etiology of the antiphospholipid syndrome: links be-
tween infection and autoimmunity. Immunobiology 2005;210: 
743-7. 
21. Amin NM. Antiphospholipid syndromes in infectious diseases. 
Hematol Oncol Clin North Am 2008;22:131-43. 
22. Devreese K, Hoylaerts MF. Laboratory diagnosis of the anti-
phospholipid syndrome: a plethora of obstacles to overcome. Eur 
J Haematol 2009;83:1-16.
23. Elefsiniotis IS, Diamantis ID, Dourakis SP, Kafiri G, Pantazis K, 
Mavrogiannis C. Anticardiolipin antibodies in chronic hepatitis 
B and chronic hepatitis D infection, and hepatitis B-related hep-
atocellular carcinoma. Relationship with portal vein throm-
bosis. Eur J Gastroenterol Hepatol 2003;15:721-6. 
24. Uthman IW, Gharavi AE. Viral infections and antiphospholipid 
antibodies. Semin Arthritis Rheum 2002;31:256-63. 
25. Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syn-
drome and infection. Curr Rheumatol Rep 2001;3:277-85. 
26. Alric L, Oskman F, Sanmarco M, et al. Association of anti-
phospholipid syndrome and chronic hepatitis C. Br J Rheumatol 
1998;37:589-90.
27. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants 
are stronger risk factors for thrombosis than anticardiolipin anti-
bodies in the antiphospholipid syndrome: a systematic review 
of the literature. Blood 2003;101:1827-32.
28. Devreese K, Hoylaerts MF. Challenges in the diagnosis of the an-
tiphospholipid syndrome. Clin Chem 2010;56:930-40.